Dec 26 (Reuters) - CASI Pharmaceuticals Inc :
* CASI PHARMACEUTICALS INC: ANNOUNCES CLINICAL HOLD OF CID-103 FOR ANTIBODY MEDIATED REJECTION $(AMR)$ OF KIDNEY TRANSPLANT
* CASI PHARMACEUTICALS: FDA PLANS TO PROVIDE FORMAL WRITTEN RESPONSE BEFORE STATUTORY DEADLINE
* CASI PHARMACEUTICALS: CID-103 IND APPLICATION SUPPORTING PHASE 1-2 STUDY OF CID-103 IN ADULTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA REMAINS OPEN
* CASI PHARMACEUTICALS: ACCRUAL TO PHASE 1-2 STUDY OF CID-103 EXPECTED TO COMMENCE IN Q1 2025
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.